Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Multicenter Phase III Clinical Study Of Nanoplatin Plus Pemetrexed Versus Cisplatin Plus Pemetrexed As First Line Treatment In Inoperable (Stage III/IV) Non-Small Cell Lung Cancer Of Non-Squamous Type

Next Previous
X
Search
Trial Profile

Randomised, Multicenter Phase III Clinical Study Of Nanoplatin Plus Pemetrexed Versus Cisplatin Plus Pemetrexed As First Line Treatment In Inoperable (Stage III/IV) Non-Small Cell Lung Cancer Of Non-Squamous Type

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Regulon

    • Most Recent Events

    • 05 Oct 2016 Status changed from planning to recruiting.
    • 12 Jun 2012 Planned number of patients changed to 880, according to a Regulon media release.
    • 12 Jun 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top